Peter Rajnics
Overview
Explore the profile of Peter Rajnics including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary
Lovas S, Obajed Al-Ali N, Varga G, Szita V, Alizadeh H, Plander M, et al.
Pathol Oncol Res
. 2022 Oct;
28:1610645.
PMID: 36262875
Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in...
2.
Szita V, Mikala G, Kozma A, Fabian J, Hardi A, Alizadeh H, et al.
Pathol Oncol Res
. 2022 Mar;
28:1610276.
PMID: 35295611
Despite the introduction of novel agents, multiple myeloma remains incurable for most patients, necessitating further therapeutic options. Venetoclax, a selective BCL-2 inhibitor, had shown promising results in patients with translocation...
3.
Varga G, Toth A, Szita V, Csukly Z, Hardi A, Gaal-Weisinger J, et al.
Pathol Oncol Res
. 2021 Jul;
27:613264.
PMID: 34257583
In Hungary, the cost of lenalidomide-based therapy is covered only for relapsed multiple myeloma (MM) patients, therefore lenalidomide is typically used in the second-line either as part of a triplet...
4.
Prenek L, Csupor K, Beszterczan P, Boros K, Kardos E, Vorobcsuk A, et al.
Int J Emerg Med
. 2021 May;
14(1):29.
PMID: 33962562
Background: Cardiac tumors are very uncommon compared to other cardiac diseases. Their clinical symptoms can vary from absent to non-specific. The most common symptoms are arrhythmias, blood flow obstruction due...
5.
Lovas S, Varga G, Farkas P, Masszi T, Wohner N, Bereczki A, et al.
Int J Hematol
. 2019 Aug;
110(5):559-565.
PMID: 31392600
Daratumumab is a human anti-CD38 monoclonal antibody used in the treatment of refractory and relapsed multiple myeloma. We investigated the efficacy and safety of daratumumab therapy in a real-world setting....
6.
Dimopoulos M, Stewart A, Masszi T, Spicka I, Oriol A, Hajek R, et al.
Br J Haematol
. 2017 Feb;
177(3):404-413.
PMID: 28211560
Trial Registration: clinicaltrials.gov identifier: NCT01080391.
7.
Kellner S, Kellner A, Haragh A, Dombi P, Karadi E, Rajnics P, et al.
Orv Hetil
. 2015 Dec;
157(1):35-8.
PMID: 26708685
Introduction: Screening for iron deficiency, which affects a significant proportion of the population, is a burning issue in the health care system. Aim: The aim of the authors was to...
8.
Kajtar B, Rajnics P, Egyed M, Alizadeh H
Ann Clin Lab Sci
. 2015 Nov;
45(5):602-6.
PMID: 26586717
The simultaneous occurrence of acute myeloid leukaemia with untreated chronic lymphocytic leukemia is extremely rare. We report a case of a 74-year-old man who was evaluated for macrocytic anaemia. Based...
9.
Stewart A, Rajkumar S, Dimopoulos M, Masszi T, Spicka I, Oriol A, et al.
N Engl J Med
. 2014 Dec;
372(2):142-52.
PMID: 25482145
Background: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1...
10.
Kollar B, Rajnics P, Hunyady B, Zeleznik E, Jakucs J, Egyed M
Orv Hetil
. 2009 Aug;
150(35):1649-53.
PMID: 19692309
Unlabelled: Over the past few decades, the occurrence of adult onset non-Hodgkin's lymphoma has significantly increased. The patient population involved is very heterogeneous, with different clinical and morphological manifestations. In...